Literature DB >> 28152619

A multinational report of technical factors on stereotactic body radiotherapy for oligometastases.

Kristin J Redmond1, Simon S Lo2, Roi Dagan3, Ian Poon4, Matthew C Foote5, Darby Erler4, Young Lee4, Frank Lohr6, Tithi Biswas7, Umberto Ricardi8, Arjun Sahgal4.   

Abstract

AIM: Oligometastatic cancer is being increasingly managed with aggressive local therapy using stereotactic body radiation therapy (SBRT). However, few guidelines exist. We summarize the results of an international survey reviewing technical factors for extracranial SBRT for oligometastatic disease to guide safe management. MATERIALS &
METHODS: Seven high-volume centers contributed. Levels of agreement were categorized as strong (6-7 common responses), moderate (4-5), low (2-3) or no agreement. RESULTS &
CONCLUSION: We present the results of a multi-national and multi-institutional survey of technical factors of SBRT for extracranial oligometastases. Key methods including target delineation, prescription doses, normal tissue constraints, imaging and set-up for safe implementation and practice of SBRT for oligometastasis have been identified. This manuscript will serve as a foundation for future clinical evaluations.

Entities:  

Keywords:  SBRT; oligometastatic cancer; stereotactic body radiation therapy; technical factors

Mesh:

Year:  2017        PMID: 28152619     DOI: 10.2217/fon-2016-0479

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  6 in total

1.  Radiotherapy for oligometastatic cancer: a survey among radiation oncologists of Lombardy (AIRO-Lombardy), Italy.

Authors:  Barbara Alicja Jereczek-Fossa; Barbara Bortolato; Marianna Alessandra Gerardi; Samantha Dicuonzo; Virginia Maria Arienti; Stefania Berlinghieri; Stefano Bracelli; Michela Buglione; Mariangela Caputo; Gianpiero Catalano; Luigi Franco Cazzaniga; Luigi De Cicco; Nadia Di Muzio; Francesco Romeo Filippone; Andrei Fodor; Davide Franceschini; Paolo Frata; Stefania Gottardo; Giovanni Battista Ivaldi; Antonio Laudati; Stefano Maria Magrini; Elisa Mantero; Ilaria Meaglia; Sara Morlino; Mauro Palazzi; Fabio Piccoli; Paola Romanelli; Marta Scorsetti; Flavia Serafini; Luciano Scandolaro; Riccardo Valdagni; Roberto Orecchia; Paolo Antognoni
Journal:  Radiol Med       Date:  2018-12-15       Impact factor: 3.469

2.  Volumetric burden of metastatic lesions drives outcomes in patients with extracranial oligometastatic disease.

Authors:  Yilin Cao; Hanbo Chen; Arjun Sahgal; Darby Erler; Serena Badellino; Tithi Biswas; Roi Dagan; Matthew C Foote; Alexander V Louie; Ian Poon; Umberto Ricardi; Kristin J Redmond
Journal:  Cancer Med       Date:  2021-10-20       Impact factor: 4.452

3.  Late metastatic presentation is associated with improved survival and delayed wide-spread progression after ablative stereotactic body radiotherapy for oligometastasis.

Authors:  Xuguang Chen; Hanbo Chen; Ian Poon; Darby Erler; Serena Badellino; Tithi Biswas; Roi Dagan; Matthew Foote; Alexander V Louie; Umberto Ricardi; Arjun Sahgal; Kristin J Redmond
Journal:  Cancer Med       Date:  2021-08-25       Impact factor: 4.452

4.  Outcomes and toxicities in oligometastatic patients treated with stereotactic body radiotherapy for adrenal gland metastases: A multi-institutional retrospective study.

Authors:  A Baydoun; H Chen; I Poon; S Badellino; R Dagan; D Erler; M C Foote; A V Louie; K J Redmond; U Ricardi; A Sahgal; T Biswas
Journal:  Clin Transl Radiat Oncol       Date:  2021-10-26

5.  Evaluation of Definitive Stereotactic Body Radiotherapy and Outcomes in Adults With Extracranial Oligometastasis.

Authors:  Ian Poon; Darby Erler; Roi Dagan; Kristin J Redmond; Matthew Foote; Serena Badellino; Tithi Biswas; Alexander V Louie; Young Lee; Eshetu G Atenafu; Umberto Ricardi; Arjun Sahgal
Journal:  JAMA Netw Open       Date:  2020-11-02

6.  A rare case of esophageal metastasis from pancreatic ductal adenocarcinoma: a case report and literature review.

Authors:  Lauren M Rosati; Megan N Kummerlowe; Justin Poling; Amy Hacker-Prietz; Amol K Narang; Eun J Shin; Dung T Le; Elliot K Fishman; Ralph H Hruban; Stephen C Yang; Matthew J Weiss; Joseph M Herman
Journal:  Oncotarget       Date:  2017-06-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.